Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: An experimental study

Anticancer Research

Volumn 32, Issue 1, 2012, Pages 95-104

  Ferreira, Adilson Kleber ^a,b   Meneguelo, Renato ^b   Pereira, Alexandre ^a   Filho, Otaviano Mendonça R ^c   Chierice, Gilberto Orivaldo ^b   Maria, Durvanei Augusto ^a,b  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF UBERABA   (Brazil)

Author keywords

Antineoplastic phospholipids; Antitumor; Apoptosis; Ehrlich ascites tumor; MTT; Phosphoethanolamine

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; HOE 33342; LIPOCORTIN 5; PHOSPHOETHANOLAMINE; PROPIDIUM IODIDE; RHODAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; ENZYME ACTIVITY; EXPERIMENTAL STUDY; HUMAN; HUMAN CELL; LIFESPAN; LIVER TOXICITY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ETHANOLAMINES; FLOW CYTOMETRY; MALE; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; SURVIVAL RATE;

EID: 84855711904     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. van Blitterswijk WJ and Verheij M: Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 14: 2061-2074, 2008.
2. Berkovic D: Cytotoxic etherphospholipid analogues. Gen Pharmacol 31: 511-517, 1998.
3. Mollinedo F, de la Iglesia-Vicente J, Gajate C et al: In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res 16: 2046-2054, 2010.
4. Mollinedo F, Fernández-Luna JL, Gajate C, Martín- Martín B, Benito A, Martínez-Dalmau R and Modolell M: Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L). Cancer Res 57: 1320-1328, 1997. (Pubitemid 27152558)
5. Jansen M, Treutner KH, Schmitz B, Otto J, Jansen P, Neuss S and Schumpelick V: Phospholipids reduce gastric cancer cell adhesion to extracellular matrix in vitro. BMC Gastroenterol 4: 33, 2004.
6. Jansen M, Jansen PL, Otto J, Kirtil T, Neuss S, Treutner KH and Schumpelick V: The inhibition of tumor cell adhesion on human mesothelial cells (HOMC) by phospholipids in vitro. Langenbecks Arch Surg 391: 96-101, 2006.
7. Jiménez-López JM, Ríos-Marco P, Marco C, Segovia JL and Carrasco MP: Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. Lipids Health Dis 9: 33, 2010.
8. Gajate C, Gonzalez-Camacho F and Mollinedo F: Involvement of raft aggregates enriched in Fas/CD95 death-inducing signaling complex in the antileukemic action of edelfosine in Jurkat cells. PLoS One 4: 5044, 2009.
9. Kumar A, Fillmore HL, Kadian R, Broaddus WC, Tye GW and Van Meter TE: The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma. Mol Cancer Res 7: 1813-1821, 2009.
10. Floryk D and Thompson TC: Perifosine induces differentiation and cell death in prostate cancer cells. Cancer Letter 266: 216-226, 2008.
11. Fei HR, Chen G, Wang JM and Wang FZ: Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation. Cytotechnology 62: 449-460, 2010.
12. Jendrossek V, Hammersen K, Erdlenbruch B, Kugler W, Krügener R, Eibl H and Lakomek M: Structure-activity relationships of alkylphosphocholine derivatives: antineoplastic action on brain tumor cell lines in vitro. Cancer Chemother Pharmacol 50: 71-79, 2002. (Pubitemid 34743999)
13. Ferreira AK, Meneguelo R, Neto SC, Chierice GO and Maria DA: Synthetic Phosphoethanolamine Induces Apoptosis Through Caspase-3 Pathway by Decreasing Expression of Bax/Bad Protein and Changes Cell Cycle in Melanoma. J Cancer Sci Ther 3: 053-059, 2011.
14. Principe P, Sidoti C and Braquet P: Tumor cell kinetics following antineoplastic ether phospholipid treatment. Cancer Res 52: 2509-2515, 1992.
15. Principe P, Sidoti C, Coulomb H, Broquet C and Braquet P: Tumor cell kinetics following long-term treatment with antineoplastic ether phospholipids. Cancer Detect Prev 18: 393-400, 1994. (Pubitemid 2156069)
16. Vink SR, van Blitterswijk WJ, Schellens JH and Verheij M: Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy. Cancer Treat Rev 33: 191-202, 2007. (Pubitemid 46323398)
17. Carrasco MP, Jiménez-López JM, Ríos-Marco P, Segovia JL and Marco C: Disruption of cellular cholesterol transport and homeostasis as a novel mechanism of action of membranetargeted alkylphospholipid analogues. Br J Pharmacol 160: 355-366, 2010.
18. Danker K, Reutter W and Semini G: Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol 160: 36-47, 2010.
19. Fujiwara K, Koike H, Ohishi Y, Shirafuji H, Kohno I, Modest EJ and Kataoka S: Cytokinetic and morphologic differences in ovarian cancer cells treated with ET-18-OCH3 and the DNA-interacting agent, etoposide. Anticancer Res 17: 2159-67, 1997. (Pubitemid 27320962)
20. Ngwenya BZ, Fiavey NP and Mogashoa MM: Anti-neoplastic action of peritoneal macrophages following oral administration of ether analogues of lysophospholipids. Eur J Cancer 28: 1637-1642, 1992.
21. Fiegl M, Lindner LH, Juergens M, Eibl H, Hiddemann W and Braess J: Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs. Cancer Chemother Pharmacol 62: 321-329, 2008. (Pubitemid 351692092)
22. Vieira HL, Haouzi D, El Hamel C, Jacotot E, Belzacq AS, Brenner C and Kroemer G: Permeabilization of the mitochondrial inner membrane during apoptosis: impact of the adenine nucleotide translocator. Cell Death Differ 7: 1146-1154, 2000. (Pubitemid 32042221)
23. Riedl SJ and Salvesen GS: The apoptosome: signalling platform of cell death. Nat Rev Mol Cell Biol 8: 405-401, 2007.
24. Danial NN, Gimenez-Cassina A and Tondera D: Homeostatic functions of BCL-2 proteins beyond apoptosis. Adv Exp Med Biol 687: 1-32, 2010.
25. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, Bazan NG, Blagosklonny MV, Blomgren K, Borner C, Bredesen DE, Brenner C et al: Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death Differ 16: 1093-1107, 2009.
26. Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol 11: 621-632, 2010.
27. Aouacheria A, Cibiel A, Guillemin Y, Gillet G and Lalle P: Modulating mitochondria-mediated apoptotic cell death through targeting of Bcl-2 family proteins. Recent Pat DNA Gene Seq 1: 43-46, 2007.
28. Vermeulen K, Van Bockstaele DR and Berneman ZN: The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer. Cell Prolif 36: 131-149, 2003. (Pubitemid 36808270)
29. Aghaei M, Panjehpour M, Karami-Tehrani F and Salami S: Molecular mechanisms of A3 adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. J Cancer Res Clin Oncol 2011.
30. Cárdenas A, Bataller R and Arroyo V: Mechanisms of ascites formation. Clin Liver Dis 4: 447-465, 2000. (Pubitemid 30460832)